GleamWall
中文EN

GDTC CytoMed Therapeutics Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1873093 · Reporting currency SGD · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY366.7%
TTM net income YoY-58.2%
TTM EPS YoY-54.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin-1,227.1%
FCF margin-1,336.5%
EBITDA margin—

Returns

ROE-51.3%
ROA-44.1%
ROIC (approx.)—
Asset turnover0.04x

Leverage & solvency

Liabilities / assets14.2%
Debt / equity0.06x
Current ratio5.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue196.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: SGD FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue324,38769,501———
R&D expense2.22M1.91M1.59M1.52M1.09M
Interest expense20,90620,31351,282125,175117,696
Pretax income-4.00M-2.52M-4.13M-3.13M-2.05M
Income tax——6531,640—
Net income-3.98M-2.52M-4.13M-3.13M-2.05M
EPS (basic)-0.34-0.22-0.39-0.40-0.30
EPS (diluted)-0.34-0.22-0.39-0.40-0.30
Weighted avg. shares (diluted)11.65M11.54M10.63M7.92M6.93M
Balance sheet
Cash & equivalents2.10M4.70M6.22M1.58M2.51M
Short-term investments——43,080——
Receivables1.57M1.03M1.10M914,144768,975
Current assets3.66M6.00M10.10M2.49M3.28M
PP&E, netmay include right-of-use assets (IFRS)3.69M3.25M2.06M2.47M2.50M
Goodwill355355355355355
Intangibles124,89493,05012,41318,80932,023
Total assets7.98M10.07M12.37M5.23M6.08M
Current liabilities709,169606,622716,9434.17M2.94M
Short-term debt40,84737,65033,926334,779385,691
Long-term debt368,656394,310407,772468,827539,119
Total debt409,503431,960441,698803,606924,810
Total liabilities1.13M1.02M1.12M4.64M3.49M
Shareholders' equity6.54M8.97M11.25M586,9802.59M
Net debt-1.69M-4.27M-5.78M-776,112-1.59M
Shares outstanding11.83M11.54M11.53M8.44M7.48M
Cash flow statement
Operating cash flow-3.70M-2.71M-3.53M-1.40M-1.71M
Capital expenditure637,8501.40M58,295473,795582,354
Free cash flow-4.34M-4.11M-3.59M-1.87M-2.30M
Investing cash flow929,2831.13M-2.73M-473,305-823,666
Financing cash flow208,648-64,89210.92M968,7164.17M
Depreciation & amortization371,042322,164374,752379,667316,666
Stock-based compensation694,200————

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, SGD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.